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active rejection. Type I is tubulointerstitial rejection withoutThe Banff 97 working classification of renal allograft pathology.
arteritis. Type II is vascular rejection with intimal arteritis, andBackground. Standardization of renal allograft biopsy inter-
type III is severe rejection with transmural arterial changes.pretation is necessary to guide therapy and to establish an
Biopsies with only mild inflammation are graded as “bor-objective end point for clinical trials. This manuscript describes
derline/suspicious for rejection.” Chronic/sclerosing allografta classification, Banff 97, developed by investigators using the
changes are graded based on severity of tubular atrophy andBanff Schema and the Collaborative Clinical Trials in Trans-
interstitial fibrosis. Antibody-mediated rejection, hyperacuteplantation (CCTT) modification for diagnosis of renal allograft
or accelerated acute in presentation, is also categorized, as arepathology.
other significant allograft findings.Methods. Banff 97 grew from an international consensus
discussion begun at Banff and continued via the Internet. This Conclusions. The Banff 97 working classification refines ear-
schema developed from (a) analysis of data using the Banff lier schemas and represents input from two classifications most
classification, (b) publication of and experience with the CCTT widely used in clinical rejection trials and in clinical practice
modification, (c) international conferences, and (d) data from worldwide. Major changes include the following: rejection with
recent studies on impact of vasculitis on transplant outcome. vasculitis is separated from tubulointerstitial rejection; severe
Results. Semiquantitative lesion scoring continues to focus rejection requires transmural changes in arteries; “borderline”
on tubulitis and arteritis but includes a minimum threshold for rejection can only be interpreted in a clinical context; antibody-
interstitial inflammation. Banff 97 defines “types” of acute/ mediated rejection is further defined, and lesion scoring focuses
on most severely involved structures. Criteria for specimen
adequacy have also been modified. Banff 97 represents a sig-
nificant refinement of allograft assessment, developed via inter-Key words: biopsy interpretation, allograft pathology, lesion scoring,
kidney, transplantation. national consensus discussions.
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Table 1. Banff 97 diagnostic categories for renal allograft biopsiesaplant patients and to establish an objective end point
1. Normal, see Definitionsfor clinical trials of new antirejection agents. The Banff
2. Antibody-mediated rejectionWorking Classification of Renal Allograft Pathology is
Rejection demonstrated to be due, at least in part, to anti-donoran international schema recently developed to fill this antibody
need. The classification, which originated in a meeting A. Immediate (hyperacute)
B. Delayed (accelerated acute)held in Banff, Canada on August 2 to 4, 1991, was pub-
3. Borderline changes: “Suspicious” for acute rejectionlished in 1993 [1], has been clinically validated in numer-
This category is used when no intimal arteritis is present, but there
ous studies [2–8], and is now widely used by center are foci of mild tubulitis (1 to 4 mononuclear cells/tubular cross
section) and at least i1pathologists and in large international trials of immuno-
4. Acute/active rejectionsuppressive agents. Subsequent meetings have been held
Type (Grade) Histopathological findingsin Banff every two years to refine the classification. For
IA Cases with significant interstitial infiltrationNational Institutes of Health clinical trials, a modifica- (.25% of parenchyma affected) and foci of
tion of the Banff grading system, the Collaborative Clini- moderate tubulitis (.4 mononuclear cells/tubu-
lar cross section or group of 10 tubular cells)cal Trials in Transplantation (CCTT) classification was
IB Cases with significant interstitial infiltrationdeveloped; this classification and a clinical validation (.25% of parenchyma affected) and foci of
study were published in late 1997 [9]. This article is the severe tubulitis (.10 mononuclear cells/tubular
cross section or group of 10 tubular cells)report of the March 7–12, 1997, Fourth Banff Conference
IIA Cases with mild to moderate intimal arteritis (v1)
on Allograft Pathology, a meeting at which pathologists IIB Cases with severe intimal arteritis comprising
.25% of the luminal area (v2)using the Banff schema and those using the CCTT modi-
III Cases with “transmural” arteritis and/or arterialfication met with clinical investigators to review new
fibrinoid change and necrosis of medial smooth
clinical and experimental observations on the pathology muscle cells (v3 with accompanying lymphoctic
inflammation)of the renal allograft, with an emphasis on mechanisms
5. Chronic/sclerosing allograft nephropathyband diagnosis of rejection.
Grade Histopathological findings
Grade I Mild interstitial fibrosis and tubular atrophy with-
(mild) out (a) or with (b) specific changes suggestingMETHODS
chronic rejection
Grade II Moderate interstitial fibrosis and tubular atrophyBanff 97, the combined classification described here,
(moderate) (a) or (b)is a product of an international consensus discussion
Grade III Severe interstitial fibrosis and tubular atrophy and
begun at Banff and continued via the Internet. This mod- (severe) tubular loss (a) or (b)
ified schema for renal allograft rejection was brought 6. Other Changes not considered to be due to rejection,
see Table 14.about through several major influences, including (a)
a The recommended format of report is a descriptive narrative signout followedanalysis of data from clinical trials using the Banff classi-
by numerical codes in parentheses. Categorization should in the first instancefication and observation of actual practice in use of the be based solely on pathologic changes, then integrated with clinical data as a
second step. More than one diagnostic category may be used if appropriate.classification worldwide, (b) publication of and experi-
b Glomerular and vascular lesions help define type of chronic nephropathy;ence in the use of the CCTT modification [9], and (c) chronic/recurrent rejection can be diagnosed if typical vascular lesions are seen.
international consensus discussions that took place at
the Second, Third [10], and Fourth Banff Conferences
and at intervening meetings. In addition, data on progno-
Banff 93–95. Nonetheless, the new version retains thesis and renal function from the Syntex/Roche mycophe-
basic construct of the earlier schema, which includesnolate mofetil trials [11], data from the CCTT trials [9],
the range of findings seen in allograft biopsies and alsoand a recent study focused on vascular lesions in rejec-
provides for semiquantitative grading of changes of bothtion [12] have demonstrated that vasculitis of any sever-
acute/active rejection and chronic/sclerosing allograft ne-ity has significant implications for response to therapy,
phropathy. To clarify the changes made, the categoriza-and graft function and outcome, and provide a major
tion and grading of acute changes are discussed in therationale for this 1997 revision (“Banff 97”). This com-
context of the earlier schemas, Banff 93–95 and CCTT.bined classification focuses on histologic “types” rather
The initial modification of the schema is a changethan “grades” of rejection. Since there are significant
in definition of specimen adequacy. To diagnose andchanges in this revised schema, there is strong incentive
categorize rejection, adequate cortex must be present inin many circumstances to retain the older classifications,
the material examined, and the change has been madebut to incorporate Banff 97 when a new study is initiated.
to ensure more adequate cortical sampling. With the
new emphasis on arteritis, a more generous minimal
RESULTS arterial sampling is also recommended. For Banff 97, an
Banff 97, presented in Table 1, represents a significant “adequate” specimen is now defined as a biopsy with 10
or more glomeruli and at least two arteries; the thresholdmodification of the grading of acute/active rejection in
Racusen et al: The Banff 97 classification 715
Table 2. Quantitative criteria for tubulitis (“t”) scorea Table 3. Quantitative criteria for intimal arteritis (“v”)
t0 - No mononuclear cells in tubules v0 - No arteritis
v1 - Mild-to-moderate intimal arteritis in at least one arterial crosst1 - Foci with 1 to 4 cells/tubular cross section (or 10 tubular cells)
t2 - Foci with 5 to 10 cells/tubular cross section section
v2 - Severe intimal arteritis with at least 25% luminal area lost in att3 - Foci with .10 cells/tubular cross section, or the presence of at
least two areas of tubular basement membrane destruction accompa- least one arterial cross section
v3 - Transmural arteritis and/or arterial fibrinoid change and medialnied by i2/i3 inflammation and t2 tubulitis elsewhere in the biopsy
smooth muscle necrosis with lymphocytic infiltrate in vessela Applies to tubules no more than mildly atrophic
Note number of arteries present and number affected. Indicate infarction and/
or interstitial hemorrhage by an asterisk (with any level v score).
for a minimal sample is seven glomeruli and one artery.
It is also recommended that at least two separate cores
containing cortex be obtained or that there be two sepa- be sought in the most inflamed areas in the biopsy. In-
rate areas of cortex in the same core. The recommenda- flammatory tubular injury and/or breakdown of tubular
tion for slide preparation is seven slides containing multi- basement membranes are included as significant histo-
ple sequential sections, three stained with hematoxylin logic findings in Banff 93–95 and the CCTT modification,
and eosin (HE) stain, three with periodic acid-Schiff and are included in Banff 97 in the “t3” grade. Since
(PAS) stain or silver stains, and one with a trichrome tubulitis is seen routinely in atrophic tubules in native
stain. The PAS stain and silver stains enhance the identi- kidneys and cannot be interpreted as a specific response
fication of glomerulitis and tubulitis and any destruction to alloantigen, tubulitis should not be graded in moder-
of tubular basement membranes. These stains also en- ately-to-severely atrophic tubules, that is, tubules re-
hance the recognition of chronic features such as arterio- duced in caliber by 50% or more.
lar hyaline, increased mesangial matrix, double contours Arteritis is likewise a defining feature for rejection
in glomerular capillaries, and thickened tubular base- diagnosis in the allograft. Both Banff 93–95 and the
ment membranes. The trichrome stain is useful in defin- CCTT formulations distinguish intimal arteritis, care-
ing interstitial fibrosis. It is recommended that histologic fully defined as lymphocytic infiltration beneath the en-
sections should be cut at 3 to 4 microns, as the current dothelium, from arteritis with inflammation in the media
definitions of lesion grading are not appropriate either and/or with fibrinoid necrosis of the vessel wall. Paren-
for 1 micron plastic sections or for “routine” thicker chymal necrosis and/or interstitial hemorrhage were rec-
sections obtained at some institutions. ognized as possible manifestations of severe arteritis by
both classifications. Banff 93–95 vasculitis (“v”) scores
Acute/active lesion scoring focused on intimal arteritis, with v1 defined as mild-to-
Semiquantitative lesion scoring provides the morpho- moderate in at least one artery, v2 as moderate-to-severe
logic basis for the rejection classification. While the basic in more than one artery, and v3 as severe in many arterial
cross-sections and/or with transmural arteritis, fibrinoidfeatures used to diagnose rejection are tubulitis and arte-
ritis, a minimal threshold for interstitial inflammation change, and necrosis. However, because there is the po-
tential for significant sampling error in defining vasculitis,must be reached to diagnose rejection of the tubulointer-
stitial type. Glomerulitis, although not a specific criterion it was agreed that the focus of grading should be on
the most severely involved vessel (analogous to tubulitisfor rejection, may have implications for late graft func-
tion, and is also graded. Tubulitis and vasculitis, as the scoring). A score of v3, or severe vasculitis (v3), is now
reserved for those cases with transmural arteritis and/orcardinal features of rejection, will be considered first.
The Banff 93–95 schema grades tubulitis (“t” score) arterial fibrinoid change and smooth muscle necrosis
with accompanying lymphocytic inflammation in the ves-based on the greatest number of infiltrating mononuclear
cells in the tubular epithelium (that is, having breached sel (Table 3). In reporting vasculitis, the total number
of arteries and the total number involved by vasculitisthe tubular basement membrane and lying beneath or
between tubular cells) per tubular cross section; if the should be recorded. If there is interstitial hemorrhage
and/or infarction, an asterisk should be added to the “v”tubule is sectioned longitudinally, results are expressed
per 10 tubular cells (the average number of cells per score. Interstitial hemorrhage and/or infarction alone
(that is, v0*), while raising the specter of rejection withcross-section). In the CCTT modification, significant tu-
bulitis is defined by number of tubules with tubulitis in vascular involvement not sampled by the biopsy, is no
longer considered adequate to presumptively score v3.10 serial high-powered fields from the area with the most
inflammatory infiltrate. Banff 97 retains a focus on most While not itself a signal criterion for rejection, a back-
ground of interstitial inflammation is required to diag-severely inflamed tubules to grade tubulitis and requires
that the tubulitis be present in more than one focus in nose rejection of the tubulointerstitial type. Because
minimal (and even significant) mononuclear inflamma-the biopsy (Table 2). The most inflamed tubules should
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Table 6. Overview of acute rejectionTable 4. Quantitative criteria for mononuclear cell interstitial
inflammation (“i”) scores
Banff 97 Banff 93–95 CCTT
i0 - No or trivial interstitial inflammation (,10% of unscarred paren-
Suspicious for acute rejection, borderline Borderline Type Iachyma)
Type IA (tubulointerstitial with t2 andi1 - 10 to 25% of parenchyma inflamed
at least i2) Grade I Type Iai2 - 26 to 50% of parenchyma inflamed
Type IB (tubulointerstitial with t3 andi3 - more than 50% of parenchyma inflamed
at least i2) Grade IIA Type Ia
Indicate the presence of remarkable numbers of eosinophils, PMNL, or plasma Type IIA (vascular with v1) Grade IIB Type II
cells (specify which) with an asterisk (*). Type IIB (vascular with v2) Grade III
Type III v3 - (fibrinoid change/transmural
arteritis) Grade III Type III
a Additionally requires at least i1 and at least 2 of the 3 following features:
edema, activated lymphocytes, or tubular injuryTable 5. Quantitative criteria for early allograft
glomerulitis (“g”) score
g0 - No glomerulitis
g1 - Glomerulitis in less than 25% of glomeruli
g2 - Segmental or global glomerulitis in 25 to 75% of glomeruli The Banff 97 classification: Acute/active rejection
g3 - Glomerulitis (mostly global) in more than 75% of glomeruli
Acute/active rejection in the Banff 93–95 schema was
divided into three grades: I, mild, characterized by mod-
erate tubulitis; II, moderate, further divided into IIa with
marked tubulitis and no vasculitis and IIb with mild-to-
tion is present in many protocol biopsies from asymptom- moderate intimal arteritis; and III, severe, characterized
atic patients, at least 10% of cortex must be inflamed by severe intimal arteritis or transmural arteritis or intra-
as a threshold for grading of interstitial inflammation. mural necrosis. In this earlier Banff classification, recent
Severe inflammation (i3) is defined when greater than focal infarction and interstitial hemorrhage without obvi-
50% of the cortex is inflamed (Table 4). Areas that ous cause could be regarded as grade III rejection. In
cannot be meaningfully graded for assessment of intersti- the CCTT modification, acute/active rejection was di-
tial infiltrates are fibrotic areas, the immediate subcapsu- vided into three types: I, with significant tubulitis; II,
lar cortex, and the adventitia around large veins and with arterial or arteriolar endothelialitis; and III, with
lymphatics. The infiltrate in classic cellular rejection con- arterial fibrinoid necrosis or transmural inflammation.
sists of T lymphocytes and monocyte/macrophages. If The Banff 97 classification of acute/active rejection-
related changes is shown in Table 6, and is compared withthere are more than 5 to 10% eosinophils, neutrophils,
rejection categories from Banff 93–95 and the CCTTor plasma cells in the infiltrate, an asterisk is added to
modification. In view of the recent studies that providethe “i” score, and other differential diagnoses should
evidence that vasculitis per se has implications for re-be considered, for example, hypersensitivity reaction or
sponse to therapy and/or graft survival [9, 11, 12], Banffinfection, as discussed later here. Moreover, the quality
97 focuses on types of rejection. Type I is tubulointersti-of the infiltrate must be analyzed in the context of clinical
tial rejection without arteritis, further divided into typeinformation. For example, tapering and withdrawal of
IA with focal moderate tubulitis and IB with severeimmunosuppression may be followed by rejection infil-
tubulitis. Type II, vascular rejection, is characterized bytrates with a substantial component of plasma cells.
intimal arteritis, further divided into IIA if the intimalGlomerulitis is graded in both the CCTT and Banff
arteritis is mild-to-moderate, and IIB if severe. Typeclassifications, although it is not used as a criterion for
III, severe rejection, is with transmural arteritis with orrejection since its significance has been and remains con-
without fibrinoid and smooth muscle necrosis. Those
troversial. The Banff schema grades glomerulitis, defined
cases with only mild tubulitis and/or with only mild focal
by mononuclear cell infiltrate and endothelial cell en- interstitial inflammation remain in a “borderline” cate-
largement, by the percentage of glomeruli involved and gory.
whether the process is segmental or global within in- As in the previous working classifications, antibody-
volved glomeruli. In the CCTT, glomerulitis may be ab- mediated rejection is also included, but now recognizing
sent, “focal,” or “severe.” The grading of glomerulitis in two forms, immediate (hyperacute) and delayed (accel-
Banff 97 is shown in Table 5, with g1 defined as glomeru- erated acute). Except in classic hyperacute rejection oc-
litis in less than 25% of glomeruli and g3 as glomerulitis curring immediately post-transplant, antibody-mediated
that is mostly global and in more than 75% of glomeruli. rejection should be confirmed by repeat cross-match, as
Polymorphonuclear leukocytes in glomerular capillaries discussed below. Antibody-mediated rejection can occur
are not a feature of transplant glomerulitis, but may be as an isolated rejection response or combined with cell-
seen in antibody-mediated rejection or in early throm- mediated rejection as an antibody-mediated component.
The morphology of classic “pure” antibody-mediatedbotic microangiopathy.
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Table 7. Quantitative criteria for interstitial fibrosis (“ci”) Table 9. Quantitative criteria for allograft glomerulopathy (“cg”)
ci0 - Interstitial fibrosis in up to 5% of cortical area cg0 - No glomerulopathy - double contours in ,10% of peripheral
capillary loops in most severely affected glomerulusci1 - Mild - interstitial fibrosis in 6 to 25% of cortical area
ci2 - Moderate - interstitial fibrosis in 26 to 50% of cortical area cg1 - Double contours affecting up to 25% of peripheral capillary loops
in the most affected of nonsclerotic glomerulici3 - Severe - interstitial fibrosis in .50% of cortical area
cg2 - Double contours affecting 26 to 50% of peripheral capillary loops
in the most affected of nonsclerotic glomeruli
cg3 - Double contours affecting more than 50% of peripheral capillary
loops in the most affected of nonsclerotic glomeruli
Table 8. Quantitative criteria for tubular atrophy (“ct”)
Note the number of glomeruli and percentage sclerotic.
ct0 - No tubular atrophy
ct1 - Tubular atrophy in up to 25% of the area of cortical tubules
ct2 - Tubular atrophy involving 26 to 50% of the area of cortical
tubules Table 10. Quantitative criteria for mesangial matrix
ct3 - Tubular atrophy in .50% of the area of cortical tubules increase (“mm”)a
mm0 - No mesangial matrix increase
mm1 - Up to 25% of nonsclerotic glomeruli affected (at least moderate
matrix increase)
rejection may be quite distinctive. In other cases, the mm2 - 26–50% of nonsclerotic glomeruli affected (at least moderate
matrix increase)antibody-mediated component is superimposed on cell
mm3 - .50% of nonsclerotic glomeruli affected (at least moderatemediated vascular changes (Discussion). matrix increase)
a The threshold criterion for the moderately increased “mm” is the expandedLesion scoring: Chronic/sclerosing mesangial interspace between adjacent capillaries. If the width of interspace
exceeds two mesangial cells on the average in at least two glomerular lobulesChronic/sclerosing changes develop in renal allograft
the “mm” is moderately increased.
with renal ischemia, hypertension, drug effects, infection,
increased ureteral pressure, and nonimmune inflamma-
tory processes, in addition to a subset due to chronic or
recurring immune reaction to the graft [13]. Chronic increase (“mm” score) is shown in Table 10. Transplant
glomerulopathy often also includes mesangiolysis andchanges may be seen in glomeruli, interstitium, tubules,
and vessels, although not necessarily simultaneously or progressive sclerosing changes; the latter may be difficult
to distinguish from membranoproliferative glomerulo-to the same degree. Because sampling error is less of a
problem in sampling of tubules and interstitium, these nephritis or, in some cases, focal segmental glomerulo-
sclerosis.features are the basis of the grading of severity of chronic
allograft nephropathy. The grading of chronic interstitial Vascular changes potentially enable identification of
kidneys with chronic/sclerosing changes due to chronicfibrosis and tubular atrophy and/or loss remains un-
changed from Banff 93–95, with quantitation based on rejection. Specific chronic vascular changes that suggest
that vascular changes are due to “chronic rejection” arethe percentage of cortical parenchyma involved (Tables
7 and 8). disruptions of the elastica, best seen on special stains, and
inflammatory cells in the fibrotic intima. Proliferation ofThe grading of chronic glomerular changes related to
rejection, previously defined by mesangial matrix in- myofibroblasts in the expanded intima and formation of
a second “neointima” are also useful features [15, 16].crease and basement membrane thickening, has now
been refined. The presence of “double contours” in cap- Fibrointimal thickening in vessels without these features
is a significant finding, especially if it is of new onset andillary loops, created by mesangial interposition, is the
most specific change of chronic transplant glomerulopa- is graded, but it is not regarded as specific for “chronic
rejection.” Recognizing that vascular changes may bethy [14], whereas mesangial matrix increase is a poten-
tially important but less specific finding. Therefore, the focal, chronic vascular changes are graded based on the
extent of occlusion of the most severely affected vesseltwo are now graded separately. Severity of chronic glom-
erulopathy is now graded by the extent of “double con- (Table 11).
Finally, arteriolar hyaline change, particularly if nodu-tours” in the most severely affected glomerulus. The
total number of glomeruli and the total number of non- lar and documented to be of new onset, may be an impor-
tant manifestation of cyclosporine or FK506 toxicity [17],specifically sclerotic glomeruli must be recorded (Table
9). An increase in mesangial matrix is graded by the as discussed later here, and has a separate lesion scoring
in the schema. The scoring of this lesion remains un-percentage of nonsclerotic glomeruli with at least moder-
ate mesangial matrix increase. Moderate mesangial ma- changed from Banff 93–95 (Table 12). Arteriolitis is a
lesion that is currently of uncertain significance; if pres-trix increase, in turn, is defined by expansion of the
matrix in the mesangial interspace between adjacent glo- ent, it is designated by an asterisk added to the “arteriolar
hyalinosis” (“ah”) score.merular capillaries to exceed the width of two mesangial
cells in at least two lobules. Grading of mesangial matrix Because it is often impossible to define the precise
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Table 11. Quantitative criteria for vascular fibrous intimal Table 13. Other non-rejection diagnoses in renal allograft biopsies
thickening (“cv”)
Post-transplant lymphoproliferative disorder
Nonspecific changescv0 - No chronic vascular changes
cv1 - Vascular narrowing of up to 25% luminal area by fibrointimal focal intersitial inflammation without tubulitis
reactive vascular changesthickening of arteries 6 breach of internal elastic lamina or presence
of foam cells or occasional mononuclear cellsa venulitis
Acute tubular necrosiscv2 - Increased severity of changes described above with 26 to 50%
narrowing of vascular luminal areaa Acute interstitial nephritis
Cyclosporine or FK506-associated changes, acute or chroniccv3 - Severe vascular changes with .50% narrowing of vascular luminal
areaa Subcapsular injury
“healing in ”a In the most severely affected vessel. Note if lesions characteristic of chronic
Pretransplant acute endothelial injuryrejection (breaks in the elastica, inflammatory cells in fibrosis, formation of neo-





Table 12. Quantitative criteria for arteriolar hyaline diabetes
thickening (“ah”) hemolytic-uremic syndrome
other
ah0 - No PAS-positive hyaline thickening Pre-existing disease
ah1 - Mild-to-moderate PAS-positive hyaline thickening in at least Viral infection
one arteriole Obstruction/reflux, urine leak
ah2 - Moderate-to-severe PAS-positive hyaline thickening in more Other
than one arteriole
ah3 - Severe PAS-positive hyaline thickening in many arterioles
Indicate arteriolitis (significance unknown) by an asterisk on ah.
fication follows earlier classifications that took the ap-cause or causes of chronic allograft damage, the term
proach of semiquantitative grading of rejection lesions“chronic/sclerosing allograft nephropathy” is preferable
to provide an acute rejection index. Finkelstein et alto “chronic rejection,” which implies allogeneic mecha-
published such a classification in 1976, in the pre-cyclo-nisms of injury, unless there are specific features to in-
sporine era [19]. This classification graded interstitialcriminate such a rejection process. However, recognition
inflammation, glomerulitis, and arteritis; intimal arteritisof those cases that do represent “chronic/recurrent rejec-
and tubulitis were not recognized separately. Mild rejec-tion” may be important, as there are preliminary data
tion had interstitial inflammation; moderate and severesuggesting that therapy may be efficacious in these cases
rejection were characterized by vasculitis. Banfi et al[18]. In chronic/sclerosing allograft nephropathy, grades
published a similar classification in the same era [20],1 (mild), 2 (moderate), and 3 (severe), as mentioned
recognizing an irreversible form of rejection with largeearlier here, may be modified by “a” (no changes strongly
artery changes and infarction. In 1983, Matas et al pro-suggestive of chronic rejection in glomeruli and/or ves-
posed a schema with eight grades, the first four definedsels present) or “b” (changes strongly suggestive of
by minimal-to-severe tubulointerstitial nephritis, catego-chronic rejection present (Table 1). If convincing diag-
ries 5 through 7 defined by minimal-to-moderate vasculi-nostic features are present, a diagnosis of “chronic/recur-
tis, and category 8 reserved for cases with severe vascularrent rejection” can be made.
rejection with fibrinoid necrosis [21]. These grades
showed a general correlation with survival, althoughThe Banff 97 combined working classification
numbers in some of the categories were too small toThe Banff 97 combined classification of renal allograft
draw firm conclusions.pathology includes acute/active rejection, chronic/scle-
Several studies have concluded that the presence ofrosing allograft nephropathy, and other morphologic
vasculitis in a renal allograft biopsy is associated withfindings, including de novo and recurrent diseases, toxic
poorer response to therapy and/or outcome. For exam-changes, and infection (Tables 1 and 13). Major changes
ple, Visscher et al found that in cases with steroid-resis-from the previous Banff schema are summarized in
tant rejection, the response to OKT3 was lower in thoseTable 14.
with vascular injury (arteritis and/or chronic changes)
[22]. Vasculitis (intimal arteritis 6 fibrinoid necrosis)
DISCUSSION has also been reported to impact negatively on allograft
survival [23]. In a pediatric series, all of those with vascu-The Banff 97 Working Classification represents input
from the two classifications most widely used in large litis (mostly severe) lost their allograft [2]. While a dele-
terious impact of vasculitis on rejection outcome has notclinical rejection trials and in clinical practice worldwide
to diagnose acute rejection. This new international classi- been a uniform finding [19], three very recent studies,
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Table 14. Changes from Banff 93, 95a nificantly less responsive to steroid therapy than rejec-
tion without endarteritis. One-year graft failure was alsoLesion scoring - Acute
severity of vasculitis is based on most severely involved vessel somewhat higher in the group with arteritis (28%) than
moderate vasculitis (v2) is now severe intimal arteritis (more than without (21%), although the difference was not signifi-
25% luminal occlusion)
cant. Conversely, severity of interstitial inflammationsevere vasculitis (v3) now requres inflammatory changes in muscle
wall and tubulitis (defined by CCTT criteria) did not correlate
interstitial hemorrhage and/or necrosis is no longer sufficient to with response to therapy or outcome.
grade v3
The threshold for rejection diagnosis is an importantthreshold for grading interstitial inflammation is more than 10% of
non-scarred cortical parenchyma component of any diagnostic grading system. It is clear
Lesion scoring - Chronic that some inflammatory changes are to be expected in
transplant glomerulopathy (cg) is now defined by “double contours” any allograft, but do not necessarily signal rejection. Ex-
cg now graded by severity in most involved glomerulus
amination of protocol biopsies in asymptomatic patientschronic vascular changes (cv) now flagged as due to chronic rejection
if characteristic changes seen has revealed that, in some cases, significant interstitial
mesangial matrix increase (mm) now scored separately inflammation may be present [24, 25]. This observation
Combined schema
led to a de-emphasis of interstitial inflammation in estab-antibody-mediated rejection replaces “Hyperacute rejection” and is
lishing a diagnosis of rejection in both the Banff andfurther defined
acute rejection now defined as “types”: I, tubulointerstitial; II, vascu- CCTT classifications. Similarly, mild tubulitis, defined in
lar; and III, severe the Banff schema as no more than four inflammatory
a Asterisks now are used to denote unusual cell composition of intersitial infil- cells in the most inflamed tubule, has been documentedtrates (1*), presence of hemorrhage and/or necrosis (v*), and arteriolitis (ah*).
in biopsies from well-functioning allografts as well and
is, therefore, not included as a criterion for rejection.
Rush et al established a protocol in which they biop-
sied asymptomatic patients at intervals post-transplantsummarized briefly later here, reach a conclusion similar
to these earlier studies, and have led to the Banff 97 [26]. Using Banff criteria, they found that approximately
one-third of these patients had “subclinical rejection,”categorization of acute/active rejection changes as “types”
(tubulointerstitial or vascular) rather than “grades” of that is, i2t2 with a less than 10% change in serum creati-
nine. Patients randomized to early protocol biopsies andrejection.
The Roche mycophenolate mofetil study [11] included treatment of this “subclinical rejection” had a signifi-
cantly lower creatinine at 24 months than those patients87 biopsies scored blinded to clinical history or outcome
using the Banff criteria. The highest tubulitis and vasculi- randomized to the control arm [27]. This finding suggests
that the threshold of i2t2 for the diagnosis of rejectiontis scores in the biopsy/biopsies obtained post-transplant
from each case, as defined by the Banff 93–95 grading is likely appropriate, even in those cases with no change
in serum creatinine, since untreated chronic graft injurysystem, were recorded. The finding of vasculitis of any
grade was significantly correlated with allograft loss. may result.
The significance of “borderline” rejection [mild tubul-Outcome, defined by graft survival, was independent of
rejection therapy cohort. itis (t1) only, or focal tubulitis with only mild interstitial
inflammation (i1)] has been difficult to define. If mildIn a study of the modified Banff grading system used
in the CCTT [9], in which type I rejection is defined by tubulitis, as defined by the Banff criteria, was included
as a criterion for rejection in the study by Rush et al,tubulointerstitial inflammation, type II by intimal arteri-
tis, and type III by arterial necrosis or transmural in- over 50% of the patients would have subclinical rejec-
tion, likely leading to unnecessary increase in immuno-flammation, there was a significant correlation of these
patterns with severity of clinical rejection. Clinically se- suppressive therapy. A few studies have looked at this
“borderline” cohort. In some series, patients with bor-vere rejection was defined in these protocols as a rejec-
tion episode that was steroid resistant, treated with ATG, derline rejection usually responded to antirejection ther-
apy; however, the finding of borderline changes withOKT3, or FK506, or was of early onset, occurring within
10 days of transplantation. The odds ratio for severe mild tubulitis does not always correlate with clinical re-
jection as defined by response to therapy [28–30]. Inrejection was 6.2 for Type I and 37.9 for Type II. Since
this classification does not provide semiquantitative some centers, biopsies are obtained after treatment is
initiated so that inflammatory changes may have dimin-grading of severity of individual inflammatory changes,
no correlations with severity of inflammatory changes ished in individuals that did indeed have a significant
rejection episode; in this circumstance, i1t2 lesions may,were defined, except that extent of tubulitis or interstitial
infiltrate did not correlate with severity. in fact, have clinical significance as an indicator of rejec-
tion. It is clear that these mild inflammatory changesIn a more recent study, Nickeleit et al analyzed the
prognostic significance of vascular lesions in rejection can only be adequately interpreted in a clinical context;
borderline changes in biopsies obtained in the context[12]. They found that rejection with endarteritis was sig-
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of decreased function may require therapy, whereas bor- major grading system that focuses on chronic changes is
the Chronic Allograft Damage Index (CADI), whichderline changes in protocol biopsies performed on pa-
tients with stable graft function may not [30]. Possible provides semiquantitative assessment of a number of
chronic and inflammatory features that have been vali-diagnoses for this category include the following: suspi-
cious for acute rejection, borderline for acute rejection, dated as clinically relevant predictors of allograft out-
come [35]. The CADI and the Banff schema have beenborderline inflammatory changes only, possible (early)
acute rejection, probable (early) acute rejection. The adjusted to provide equivalent information.
It must be emphasized that although rejection-relatedfinal designation may depend on center experience, ther-
apy, time after transplant, and other clinical and morpho- changes are a focus of the Banff 97 schema, there are a
number of other disease processes that may involve thelogical features, including other signs of inflammatory
cell activation or tissue injury. allograft and must be considered in the differential diag-
nosis (Table 13). Those processes that produce inflam-The criteria for rejection diagnosis in the CCTT modi-
fication included tubulitis plus two of the following three matory changes in the allograft must be differentiated
from acute rejection. Polymorphonuclear leukocytescriteria: interstitial edema, activated lymphocytes (or
blasts), or tubular injury. However, on evaluation of the (PMNL) in the interstitium and especially in tubular
lumina may signal acute bacterial infection, althoughindividual pathologic criteria for rejection, removal of
these three additional criteria resulted in reclassification they may be seen in cases in which there is significant
ischemic injury and infarction (which may in turn beof only two cases, one that responded to antirejection
therapy and one that did not [9]. Moreover, in those rejection related). If PMNL are confined to peritubular
and glomerular capillaries, the possibility of severe acutecenters in which biopsy is frequently performed after
steroid bolus therapy, edema and activated lymphocytes endothelial injury and possible antibody-mediated rejec-
tion must be considered. While numerous eosinophilsare much diminished within one to two days. These addi-
tional criteria, however, may occasionally be useful when may be a feature of the inflammatory response to alloan-
tigen, the possibility of a hypersensitivity reaction mustcombined with other morphologic findings and in clinical
context in those cases with borderline changes [31]. be in the differential as well.
Viral infections must always be considered, as in-Type I and type II rejection are both thought to be
manifestations of cell-mediated rejection. However, type flammatory infiltrates in this setting are typically mono-
nuclear, and significant tubulitis may be seen. The speci-II may be seen in and type III is strongly suggestive of an
antibody-mediated component to the rejection process. men should be examined carefully for evidence of viral
cytopathic features such as megalic cells, nuclear smudg-Other pathologic features suggesting an antibody-medi-
ated component have been identified in cases in which ing, or intranuclear or cytoplasmic inclusions. If the clini-
cal or pathological index of suspicion is high, immunohis-antidonor antibody has been identified [32, 33]. These
features include widespread endothelial injury with more tology or in situ hybridization can be used to enhance
identification of viral agents. Cytomegalovirus [36], poly-severe vasculitis (frequently accompanied by fibrinoid
changes in the vessel walls), glomerular and small vessel oma (BK) virus [37], and adenovirus [38] may all infect
the allograft. Colvin believes that relatively severe tubu-thromboses, infarctions, glomerulitis, marginating cells,
and especially polymorphonuclear leukocytes, in peritu- lar cell injury with relatively mild inflammation should
suggest the possibility of a viral infection [39]. Infectionbular capillaries. When these features are prominent, the
biopsy findings should be graded according to the Banff may, of course, coexist with rejection, making diagnosis
and therapy problematic.criteria, and the possibility of an antibody-mediated re-
jection component should be indicated as well. The pres- Plasma cells may likewise be a component of the rejec-
tion response, but may also signal infection. If the plasmaence of antibody-mediated rejection should be confirmed
by a repeat donor-specific cross-match. cells are part of an aggressive infiltrate, that is expanding
and displacing normal structures, and especially if theBanff 97 also includes grading of chronic/sclerosing
change in renal allograft biopsies. This remains an impor- cells are atypical, post-transplant lymphoproliferative
disorder (PTLD) must be ruled out. The separation oftant component, as most allografts are now lost to often
slowly evolving and clinically indolent sclerosis in the renal Epstein-Barr virus (EBV)-associated PTLD from
severe acute rejection at biopsy remains very important,allograft. Recognizing that the tubulointerstitial changes
are most accurately sampled and have the strongest cor- as the appropriate treatment is reduction of immunosup-
pression for PTLD, but aggressive anti-T-cell therapyrelation with outcome in native as well as allograft kid-
neys [34], the grading of severity of chronic rejection for severe rejection. Potential differential features have
been identified [40]. PTLD typically shows expansile orcontinues to focus on interstitial fibrosis and tubular atro-
phy and loss. However, identification of distinctive vascu- nodular mononuclear infiltrates with irregular foci of
serpiginous necrosis. PTLD lesions may be focal or dif-lar changes may enable the diagnosis of chronic rejection,
which in turn may be amenable to therapy [18]. The other fuse, and the latter may result in extensive involvement
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of the pericalyceal adipose tissue and nerves. The infil- olar hyaline eosinophilic deposits comprised of fibrin,
IgM, C3, and C1q, which may be difficult to distinguishtrates in PTLD generally show the entire spectrum of
lymphocyte differentiation, including immunoblasts, from those due to aging, hypertension, and diabetes mel-
litus. As with CsA, arteriolar myocyte vacuolization canplasma cells, large cleaved/noncleaved cells, and small
round lymphocytes. Cells with marked nuclear atypia be seen; this lesion is a nonspecific manifestation of vessel
spasm and should be ascribed to tacrolimus toxicity onlyare usually present and help in the differential diagnosis
from rejection. Some biopsies have a monotonous ap- after exclusion of other causes of vessel injury. Drug-
induced vasospasm and the hyalinization of the interlob-pearance, and such patients may be histologically and
clinically indistinguishable from intermediate-to-high ular arteries and arterioles may lead to ischemic injury
accentuated in the medullary rays and probably also thegrade lymphomas in nonimmunocompromised patients.
Although they are not as readily found as in severe medullary inner stripe [48], leading to striped or diffuse
interstitial fibrosis.rejection, PTLD cells can also be associated with tubul-
itis. Of course, rejection and PTLD can coexist in a Significant tubulointerstitial inflammation or vasculitis
may also be components of recurrent or de novo renalbiopsy [41], making accurate diagnosis especially diffi-
cult. In most cases, and especially with limited biopsy disease in the allograft. These differential considerations
must be considered at any time post-transplant and be-material, the final diagnosis must await the results of
immunophenotyping, and EBV in situ hybridization. come more likely as time post-transplant increases. A
good pretransplant clinical history can be invaluable inWith rare exceptions, PTLD lesions are B-cell prepon-
derant and EBV positive, whereas rejection is associated considering differential diagnoses.
Finally, future advances in analysis of renal allograftwith a primarily T-cell infiltrate, which is EBV negative.
CD20 (B-cell marker) and CD3 (T-cell marker) immu- biopsies can already be predicted, and the classification
and grading of acute/active rejection will continue tonohistochemistry is a reliable way of phenotyping infil-
trates in formalin-fixed material. The most sensitive tech- evolve. The significance of specific morphologic find-
ings—including glomerulitis, arteriolitis, and infiltratesnique for demonstrating EBV in routinely processed
tissue is in situ hybridization for EBV-encoded small with unusual cellular features—for acute and chronic
allograft function and outcome will continue to be inves-RNA [42]. In lesions with significant numbers of plasma
cells, staining for kappa and lambda light chains is a tigated. Emphasis in biopsy assessment will shift from
diagnosis to prediction of later allograft function andconvenient way of identifying lesions that are clearly
clonal. If sufficient fresh tissue is available, immunoglob- outcome, potentially enabling early intervention. In-
deed, two recent studies have shown that chronic histo-ulin gene rearrangement and oncogene studies should
also be performed, as molecular findings have also been logic changes detected in early protocol biopsies and
graded using the 93–95 Banff schema were predictiverelated to ultimate prognosis [43].
Toxic effects of cyclosporine and of tacrolimus also of long-term outcome [49, 50]. Clinical utility of renal
allograft biopsies, for both diagnosis and prediction ofremain important differential considerations. Toxic ef-
fects of cyclosporine have been studied for some time, outcome, will be enhanced by application of immuno-
staining and molecular studies. Identification of effectorbut tacrolimus is a relatively new agent, and its toxicity
profile is still being defined. Cyclosporine and tacrolimus cells such as NK cells and cytotoxic T-lymphocytes and
of monocyte/macrophages may enhance diagnosis and/share a closely related mechanism of action, which is
paralleled by an overlap in the toxicity profile of these or predict later dysfunction. Molecular studies show
promise in refining the diagnosis of acute/active rejectiontwo drugs. The pathology of tacrolimus nephrotoxicity
appears to be similar to cyclosporine toxicity [44–47], [51], although much more needs to be done to establish
validity in cases with borderline features and to dissemi-although it has been much less completely studied. Tubu-
lar vacuolization is the most common finding in biopsies nate the technology. It will be important to establish
which molecular markers correlate with interstitial infil-performed during clinical episodes of tacrolimus nephro-
toxicity; tubular vacuoles may be seen in proximal as well trates and which correlate with invasive inflammation
(tubulitis, intimal arteritis). Also, more precise definitionas distal tubules, and although these are often isometric,
focal coalescence into larger vacuoles is also present. of histologic and molecular features of indolent graft
injury and sclerosis should enable better understandingAs with cyclosporine, tacrolimus therapy may also be
associated with microvascular toxicity characterized by of pathogenesis of progressive damage and enable ap-
propriate therapy. There is clearly much work to be donedamage to the glomerular capillaries and renal arterioles.
Arteriolar damage mediated by tacrolimus sometimes in optimizing the assessment of the renal allograft by
the pathologist as we move into the 21st century. Manyresults in an acute arteriolopathy characterized by endo-
thelial swelling, mucoid intimal thickening, eosinophilic of these issues will receive focused attention at the Fifth
Banff Conference on Allograft Pathology in 1999 and inglobules in the media, and focal medial necrosis. Scat-
tered thrombi may be seen in capillary loops or afferent other international forums, which have become logical ven-
ues for such consensus in the global medical community.arterioles. Prolonged tacrolimus therapy results in arteri-
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